Greetings, and welcome to the Celanese First Quarter 2023 Earnings Call and Webcast. [Operator Instructions]. At this time, I'd like to turn the call over to Brandon Ayache, Vice President of Investor Relations. Thank you. You may begin.

Thank you, Darryl. Welcome to the Celanese Corporation first quarter 2023 earnings conference call. My name is Brandon Ayache, Vice President of Investor Relations. And with me today on the call are Lori Ryerkerk, Chairman of the Board and Chief Executive Officer; and Scott Richardson, Chief Financial Officer. Celanese distributed its first quarter earnings release via Business Wire and posted prepared comments on our Investor Relations website yesterday afternoon. As a reminder, we'll discuss non-GAAP financial measures today. You can find definitions of these measures as well as reconciliations to the comparable GAAP measures on our website. Today's presentation will also include forward-looking statements. Please review the cautionary language regarding forward-looking statements, which can be found at the end of both the press release and prepared comments. Form 8-K reports containing all of these materials have also been submitted to the SEC. Since we published our prepared comments yesterday, we'll go ahead and ask you, Darryl to open it up for questions.

[Operator Instructions] Our first questions come from the line of Michael Leithead with Barclays.

First question, Lori, just high level on the full year EPS guide. You're doing about 450 of EPS in the first half, which implies about $7 in the second half. I assume synergies, Clear Lake, a few other things are helping in that back half. So I guess, is there a way to broadly characterize what you're assuming for market demand recovery in the second half versus, say, controllable actions?

Yes. Thanks for the question, Mike. I mean you're right. We need about on average $1 lift in Q3 and Q4 from where we were in the first half. And so our focus really is on controllable actions to the extent we can. I mean, M&M volume recovery we saw about a 10% lift from Q4 to Q1, a similar lift from Q1 to Q2. We continue to expect volume recovery in the M&M business as well. Productivity, which is coming in at the top of our range for all of our businesses, M&M price optimization, synergies, which we'll see building across the quarter. We also do expect some improving demand again for in its entirety. We were up about 10% in the first quarter. We'll have some increase again in Q2, but we do expect things to get better still in the back half of the year. As we see kind of the EU and Asia competitive dynamic improving and see the in destocking in the U.S. And then we should have some tailwinds from raw materials and energy cost moderation, which should help with margins in all of our businesses and especially in EM as we see those costs flow through to inventory. And start to hit the P&L. So I think that's kind of what we're in control of. In terms of where we see the markets going, if we take it first by region, in China, we do expect modest demand improvement in Q2 and into the second half. We do see markets recovering in China, especially auto. And we continue to see some improvement in utilization in acetyls and hopefully get acetyls coming off the cost curve. Especially now as we're going into some turnarounds in Asia, we do see some upward price movement and…

Great. That's super helpful. And then maybe second, you talked in the prepared commentary, Lori, a bit about some of the integration actions you're taking in nylon 66 I was just hoping you could expand a bit about how you're currently thinking about your approach to the 66 value chain and just maybe how Celanese going forward might be operating differently than, say, M&M stand-alone nylon polymerization business or just even the legacy Celanese compounding business there?

Yes. So let me talk a little bit about 66 in general, starting with what we're doing immediately around 66. So in the past, Celanese has not been backward integrated in 66. So we were just a purchaser of nylon Polymer, which was great when prices are low, not so great when prices are high. With DuPont, we've been able to add the backward integration. What we're doing differently is we've been able to secure a different raw material contract and instead of being forced to produce PA66 polymer we have options. We have flexibility. We have optionality. We can choose to produce backward integrated nylon polymer when it makes sense, we can make less and buy nylon polymers, from others, if that makes more sense, we can make less of it if we see the demand profile not supporting higher production rates, and we can make more of it if we see a sudden resurgence of demand. And so that flexibility, which is much more like we run our other businesses like GUR and Palm and even acetyl, gives us a degree of flexibility and ability to make value across a wide range of market conditions that DuPont really didn't have or really didn't exercise. And so we've already done that. We've gotten most of the Celanese nylon grade already certified to start with the DuPont polymer. We've been using DuPont polymer out of inventory, raw home, compounding it to make the Celanese branded products and we've been flexing that to really start managing some of the inventories that had been built last year for both raw and for finished polymers in the DuPont product line. And so that's a degree of flexibility and a way of running the business, which is different. We've also talked about how we're…

Our next question has come from the line of Jeff Zekauskas with JP Morgan.

I think you reduced your earnings per share goal by dollar. What was the source of a decrease?

Yes. If we look at the first half, our first half came in about where we -- in total, where we expected the first half to come in with 1Q being up because of some unanticipated commercial opportunities for spot market volumes as well as some pull forward from the second quarter, especially in auto, a few parts for auto and a few for medical implants. And so since we don't expect those -- we're not counting on those unexpected opportunities reoccurring in the second quarter. Second quarter has been a little bit lower. And we are seeing the demand in the second quarter not build as quickly as we had thought at this time last quarter. And so that reduction to $11 to $12 really reflects that slower demand growth that we're seeing across second quarter going into third quarter and just accounting for that in our outlook for the second half.

Is it fair to say that as a base case, second quarter volumes and prices are flat sequentially?

I expect for volume for Engineered Materials. We should see the volumes increasing moderately across the second half, especially in M&M as we have market share recovery and just base business demand increasing in automotive and some of the other end applications. I think for acetyls, we also expect moderate growth into the second quarter as we start to see more recovery in the end markets. right now for acetyl, pricing is a little -- is challenged, although we are seeing some early green shoots on China asset pricing and margin expansion, it's very new, though. So although we've baked what we've seen so far into our projections, we think there's still some more room there, possible upside there. And I think for Engineered Materials, we do expect some margin expansion as we go to the second half particularly as we see the lower raws and energy costs from the first half pulling through the volume and inventory, which will help with margin expansion in the second half.

Our next questions come from the line of Ghansham Panjabi with Baird.

Thank you. Good morning, everyone. Lori, maybe you could just give us a bit more color on the demand spike that you saw in March, maybe stepping back. Is there any -- was there any sort of theme in particular that you can hone in on any region in particular that saw that increase? And as you kind of step back, was it more so of a pull-forward from 2Q that benefited March, do you think.

Let me talk about that a little bit. So as we saw in March, what we saw in March is we saw our books starting to really -- at the time of the call, we were really seeing good volume showing up on our books for in our base businesses, and that gave us some confidence about second quarter. I think the unanticipated commercial opportunities that we saw, though, at the end of March, which really got us above our guidance was a number of things. One, there were some unusually high spot demand at the end of the quarter. So things like Palm and nylon, also to an RDP, so it was across both of our businesses. And I think because of our flexibility we have in our supply chain and our operations, we were able to capture a significant share of that unexpected volume that arose at the end of the quarter. I would say that was the majority of that. I think though we also did see accelerated by in a few products in auto and in medical implants, which is a little unusual because we had expected quite a big headwind from medical implants and in fact, had some orders come in. In the case of medical, I think that probably pulled forward from Q2. In auto, we think it's also some pull forward from Q2 in anticipation of better demand in Q2. So I think on that one, is it pull forward? Or is it just quicker demand recovery? Not sure yet. That's not clear. But we're kind of characterizing it as pull forward until we see if that's a sustainable trend.

Got it. And then as it relates to the U.S. and your comments on destocking, just a bit more color there in terms of which particular end markets I assume construction is part of that. But just to hear your thoughts. And then just judging by destocking that's occurred in other geographies, including in Europe, what do you think is a reasonable time line in terms of the destocking event? Is it 2 quarters, 3 quarters? How are you thinking about it now?

Yes. What I would say, is we really saw the end of destocking in Europe and Asia for the most part as we moved into the second quarter. What we've really seen destocking continue is in the U.S. And there, auto is pretty robust, I would say, across all of the areas. But I think there, we see destocking continuing in consumer goods and industrial for the most part. And right now, our projection is we think that's going to continue through second quarter, but be pretty much over as we move into the third quarter, and that's some of the uplift we expect to see in the second half.

Our next question has come from the line of Michael Sison with Wells Fargo.

Lori or maybe Scott, you started the first quarter with negative free cash flow. Can you help us walk into the 1.4? You maintain free cash of 1.4. How does that sort of unfold, do we turn positive in 2Q? Or is it more second half loaded?

Yes. I mean we expect it to be negative just kind of coming off of where Q4 was from a sales perspective and then kind of when we had the interest payment. So as we walk into the second quarter, you've got higher levels of earnings coming through. We also had really abnormally high CapEx from a cash perspective in the quarter as well as cash taxes being higher. That goes away at a higher level. We're at more normalized levels in the balance of the year. With the higher earnings levels coming through now in the balance part of the year, we would expect to be able to kind of get up and average much higher levels as we go forward. That sequential walk from Q1 into Q2 is about a $700 million lift from where we were in the first quarter when you kind of put all those things together.

Got it. Okay. And then I think in your prepared remarks, you said that 50% of the first quarter EPS came in March. So April is at a buck -I'm sorry, March is at back then if you think about April, May, June, it typically is better than March, I think. So what happened, do you think in terms of decelerate -- the deceleration into April, May and June, and I thought maybe that dollar could have sustained throughout the quarter.

Yes. Again, Mike, I would say a significant portion -- or a portion, I should say, of that dollar in March really was related to the unanticipated and spot like opportunities we were able to capture in March. And so we've not seen those repeat in April, and we haven't baked them in as repeating later in the quarter. Whereas the base level of earnings has continued to grow -- will continue to grow moderately across the months. So I think we're just trying to be realistic in terms of what we think is repeatable and what was fortunate. Again, we're positioned to take advantage of those spot opportunities if they were to arise again, but we don't want to bake that into our forecast.

Our next questions come from the line of Matthew DeYoe with Bank of America.

So it looks like you beat your 1Q M&M EBITDA guidance and 2Q is expected to accelerate. But the prepared comments no longer mentioned that lift to like $700 million to $750 million in EBITDA. Are you walking away from that level what do you kind of expect M&M can deliver this year for EBITDA?

Thanks, Matt. We're really happy with how the integration is going and the value uplift we're starting to see in the M&M assets. Our concern at this point is the fact that second quarter is not accelerating at the pace that we thought across all of our businesses. And so we're going into the second half. At a little lower demand rate than we had originally called out last quarter. So that applies to M&M as well. And so what we're really focused on now, so what I would say is, if that plays out the way we see now, I would say we're kind of at the lower end of that $700 million to $750 million that we called out. And so what we're really trying to get our teams to focus on is making sure we're delivering growth. So that as we get towards the end of the year, we are basically on track for EPS neutral quarter going into 2020, either sometime in the second half or going into 2023, which would be at that kind of $200 million EBITDA range, including synergy.

And can you talk a little bit more about the product flow out of China and PLM into Europe? PLM is not really a product, I have a ton of line of sight into. So maybe kind of give me an idea of where margins are in Europe now versus China or what the theoretical kind of compression risk looks like to the European business, how far along we are and maybe some of that are closing from European product or a Chinese product?

Sure. really started back in the fourth quarter and when we really started seeing -- or really even through the third quarter last year when we really started seeing the very high energy prices in Europe. That raise the price of palm in Europe and provided an arbitrage opportunity for Palm coming out of Asia, both China and Korea out of Asia into Europe because demand was very low in Europe. And so that -- those molecules found a home in Europe, where it could be highly competitive even with the shipping cost to do the -- to be there. Now obviously, with the COVID resurgence in December, and going into the first quarter, we saw those volumes still flowing in the first quarter, even as we started to see energy prices coming down, in Europe, but because of the lack of demand in Asia, there was still an opportunity to move projects into Europe. And while we still see volumes moving in the second quarter, we really expect that now demand is coming back up in Asia that those molecules will find a home again in Asia, prices are down and competitive in Europe. With that on a landed basis. And so we should see those prices stabilizing again in Europe, I think as we move through this quarter and into the third quarter.

Our next questions come from the line of Josh Spector with UBS.

Two questions, maybe I'll roll into. One here is you seem to pull a lot of levers to basically keep free cash flow in the range that you provided, despite the cut to earnings. Just curious, one, what levers are left if things will play out as you see it and two, as you look at your guidance, I mean, you're talking about demand improving. I guess does the lower end of your range reflect the scenario where demand doesn't really improve from 2Q levels? Or would that be another cut that we need to consider?

Yes. Let me start with your kind of last question first. I think the lower end is a range that we feel is achievable even with only really moderate growth. And there are some areas we know like auto, we feel quite comfortable we'll continue to grow this year at a very moderate pace because of the pent-up demand for auto. So I would say the -- we feel very confident in the $11, short of a global recession, on the $11 end of our outlook and our cash flow reflects that. But I mean, if we were to say, go into a global recession, we have a really unexpected downturn here well beyond anything that any of us are imagining right now. There are still levers within cash flow, and we saw that in 2020 with COVID. So if we really see that kind of scenario develop our demand goes down. One, we'll have more working capital release because the value of inventory goes down, we'll be able to go down to even more minimum inventories. But we would also have cost savings as we would take steps similar to what we did during COVID to slow production rates possibly even shut down plants for a period of time, and you have cost saving benefits that come from that. So I mean, I think we feel very comfortable in our ability to deliver the level of cash flow that we've indicated given the steps that we've already called out

Okay. And just a quick follow-up just on the inventory adjustment in 2Q, kind of thinking along against similar scenarios here, is that something contained within 2Q? Or is that something that drags into the second half is what's baked into the outlook there?

Yes. So we're assuming any working capital release from inventory of $300 million or more. So if you think about 2Q, that's a $100 million reduction in working capital and that comes with 30 to 35 impact on EBITDA -- EBIT. So as we go forward, you would expect to see that same impact continue through the second half as we take other inventory adjustments. Obviously, different inventory adjustments come at a different EBIT and depending on what pricing is doing, but I would expect to see some impact from inventory as we move through the year.

Yes. And Josh and that's all baked into the guide that we gave.

Our next questions come from the line of Kevin McCarthy with Vertical Research Partners.

Lori, would you elaborate on your acetyl outlook in China? If we look at some of the consultant assessments of acetic acid prices they really haven't done a whole lot over the last 2 months or so. But in listening to your commentary, it sounds like maybe there's some upward tension building there. If that's correct, would you attribute that to some of your competitors' outages over the next month or 2? Or do you foresee a more sustained cyclical uplift as the year plays out.

Yes. Thanks for the question, Kevin. So as tills in fourth quarter was definitely sub foundational, and I think we talked about that. I mean we're really essentially at the cost curve and in some periods of time during the quarter and fourth quarter and even into first quarter, even below the cost curve from time to time. So what's happened is if you look at coal pricing in China, coal pricing, why asset pricing has remained at about the same level for the last several months. We've actually seen coal pricing come down from Q4 to Q1, coal pricing came down about 20%. And so you see some uplift in the actual margin. So now we're still very close to the cost curve in terms of margins, but it stabilized a little bit through first quarter. And then some of the turnarounds, which we expected to happen in the first quarter got pushed to second quarter. We're starting to see those turnarounds start. And as that takes capacity out of the system, that further tightens the [flight-fly] demand situation we see margins slowly creeping up. And just really in the last 5 days, we've started to see a slow increase in acetic acid pricing which we baked that into our guidance, that small increase that we've seen. But I'd say it's still early. We need to see if that's sustained. But we think there is a chance that is sustained with now the more normal level of outages we expect going forward. I mean the last 6 months have been remarkably stable in the acetic acid world. I mean not a lot of unplanned downtime, not a lot of increases in demand, not a lot of planned downtime. And I think we're going into a more typical period now where we will have occasional outages, both planned and unplanned, which will give us periods of market tightness that we'll be able to take advantage of.

And then secondly, for Scott, can you speak to your debt reduction target for this year? You affirmed your free cash flow or at least endorsed free cash flow 1.4 billion. I think that number excludes the proceeds that you expect from your Mitsui deal which I understand to be $400 million or more. And so can you put that into context in terms of how you can attack the balance sheet over the next 8 or 9 months here?

Yes. Thanks. Kevin. If you go back, we had stated a goal of reducing net debt by $1 billion in 2023. With the cash flow that we expect, we'll certainly do that. And when you layer in the Mitsui proceeds on top of that, certainly, will well exceed that net debt reduction target that we had when we first announced the deal a year ago, of $1 billion. So we feel good about where we finished the year from a net debt perspective. And then given what Lori talked about earlier on where we would expect from an earnings trajectory to exit the year as we drive cleanup of the inventory on the balance sheet and we start expensing much lower cost inventory as we go into the second half and then exit the year, we feel good about the earnings trajectory to get to that 3x target that we had initially stated by the end of 2020.

Our next questions come from the line of John McNulty with BMO Capital Markets.

This is [Babesh] for John. I would like to hear your thoughts on the competitive landscape in Europe between your businesses. In your prepared remarks, you mentioned some price concessions you offer there in Yen. Any changes to your competitors or perhaps a change in the product mix that is happening there? And then on asset deals, all your competitors have the level of flexibility you mentioned of moving products from Asia. So assuming things are not as easy as you for your competitors, any changes in market share or capacity there.

Yes. In terms of the competitive landscape in Europe, I think the real challenge there has been imports from Asia, again, reflecting the low demand in Asia and the improved cost position Asia had compared to Europe when they had much higher energy prices. And I should say Europe energy prices have come down significantly, but they are still high relative to the rest of the world. And so again, we see that situation improving, especially now with increased demand developing in Europe. We really see that having improved now at the end of the first quarter going into the second quarter and then further improving in the second half of the year. On Steel's competitiveness, it has been a very stable market. So it's been very competitive as there's -- and it's also been a period of seasonably low demand for acetyls as well as some of the impacts of China holidays and just lower China demand and the slowdown in the construction industry globally and the impact that has on acetyls. Again, as we start to see recovery, even slight recovery in Europe and Asia in construction, as we start the normal levels of shutdown, we do see an opportunity there to capture additional margin in the acetyl space. the ability to capture additional market share is really based upon our commercial model and the optionality and flexibility we have to take advantage of when there are spot opportunities by moving molecules around the globe by flexing up and down our product chain. In first quarter, we took advantage of the stronger markets for emulsions and RDP further down the chain, which helped boost our profitability in the first quarter. As we start to see some movement in the asset price in China, there will be an opportunity to take advantage of it there. So it really is all around more so than market share, it's more around the flexibility and optionality and the ability to capture in any given market at any given time, any upside potential that exists.

Got it. And secondly, on clean, congrats on the commissioning there. You mentioned $100 million worth earnings contribution next year. Is this all incremental to your overall global earnings level -- or will some of it be offset by, say, reduced operating rates somewhere products in China where you're running close to your cost curve?

Yes. So the $100 million is on top of our already kind of $1.3 billion level of foundational earnings for Acetyl so that's raising the total global acetyl Foundational earnings from to 1.4. And think about it, it's really about 50% based on what I call ratable productivity, so things like reduce catalyst costs, reduce energy costs, reduce maintenance costs, et cetera. And then about 50% of it is based on having kind of built-in turnaround and outage coverage in the network by having 2 units at Clear Lake. And then obviously, there's additional upside to that if we were to get in a period of higher demand and higher pricing to basically raise our output from -- in totality of our acetyl chain.

Our next questions come from the line of Frank Mitsch with Fermium Research.

Yes. Congratulations on the mechanical completion for the Clear Lake acetic acid facility. I know you gave some earnings projections for the balance of the year and for next year. I was just curious as to how this is going to impact your operating rates at some of your other facilities. How should we think about the industry overall and the impact that this may have.

Yes. So thanks, Frank. We are happy to have the mechanical completion behind us, and we're moving now into the commissioning phase and anticipate production in Q3. Look, at the lower natural gas prices we're seeing, which greatly advantages our location there in Clear Lake. I would anticipate you would see that facility running at higher rates, which could reduce rates because of global demand. Reduce our operating rates in China and Singapore as we continue to supply Europe from the U.S., and we'll be able to supply Europe even at higher volumes entirely now coming out of the U.S., and it's cost effective to do so. I don't know that you really see opportunistic shipments to Asia. Although that's possible in the second half, the volume of that, though, is limited. I mean, there are other supply constraints around availability of vessels and availability of receiving tankage, et cetera. But that arbitrage could open up as well. I think what we need to realize is Clear Lake is not only the lowest cost producer of acetic acid now in the world. And we'll be able to produce a significant volume of it, but it is also the lowest carbon footprint producer of acetic acid in the world. And so we think that is going to bring -- open up a lot of opportunities for Clear Lake and from the impact on the industry, clearly, I think it will make some impact in terms of volumes you see moving from Asia to Europe as we'll be able to service volumes in Europe much more cheaply from the U.S.

So the intent would be to run that flat out and ramp back some of the operating -- ramp up some of your other facilities. Where do you think operating rates are in acetic acid as we look at the second quarter. And then, of course, you guys recently restarted your non-Zing VAM facility. If you could talk about operating rates in the VAM area as well, that would be helpful.

Yes. Look, industry operating rates for both globally for both aceic acid and VAM are still kind of in that 90% range. maybe from time to time a bit lower, but are still kind of trending towards that 90% range. It just has been so stable, which is a little bit unusual in this business. For the last 6 months that people have gotten comfortable at those operating levels and demand has been down, again, normal seasonality. And so it feels quite comfortable. But at 90%, I mean, we are now positioned to take advantage of really any -- either planned or unplanned downtime that occur globally in either asset or BAM or any of the downstream derivatives. And that's really where we've seen the opportunity in the past is when we start getting some either regional or short-term misallocation between supply and demand

Our next questions come from the line of Vincent Andrews with Morgan Stanley.

I wanted to follow up on that a little bit on the demand side of the equation because one of the issues I’ve been having in our own S&D models here is trying to sort of reconcile what I think the underlying demand number is versus what shipments have been to try to account for. Obviously, we had a lot of issues with unplanned outages over the last few years, but we also had very strong building and construction demand in the acetyl chain. So how do you reconcile that when you sit here today and think about what the actual underlying instant demand is versus shipments and maybe how much shipments might have overstated demand in the past and maybe understating demand now in terms of thinking through what operating rates can look like over the next couple of years.

Yes. Look, it’s been a bit of a confusing time and Frank, I would say. If we look at fourth quarter last year, when prices were very low, we started seeing demand really coming off, particularly in Asia, although operations were fairly stable, we certainly still saw some molecules moving as people anticipated different things. And as we go forward, we also saw a lot of shipment and people carrying higher inventories before that because of all of the supply chain issues that existed around the world, and you call like in the first half of 2022. VAM and emulsions, I mean, there just wasn’t even enough molecules out there to meet the customer demand. And so people were carrying a lot higher inventories when we saw the reduction in demand through the fourth quarter, we saw people really destocking in the fourth quarter. We called that out at the last earnings call. I would say now as we’ve moved through the first quarter and especially March and beyond, we do see demand recovery coming back for fibers for other end users. Construction is still, I’d say, the weak spot, although even in – like in Asia, we’re seeing a little bit of recovery in construction. And in Europe, we’re seeing recovery in construction, not so much in new builds, but in renovation for energy efficiency, where a lot of our downstream derivatives products go. So we are seeing the demand coming back again with a few exceptions. And so that is starting to bring the volumes up. But we’re not really seeing restocking occurring yet as people feel fairly comfortable because we’ve been in such a stable period and haven’t had the supply chain issues. I think customers feel fairly confident they can get the materials they want. As we see demand continue to increase, I expect we’ll see some level of restocking. And with that higher demand, we should see some tightening of pricing and seeing some pricing uplift across all the regions.

Our next questions come from the line of Arun Viswanathan with RBC Capital Markets.

I guess the first thing was you noted about $1 of uplift from 2Q into 3Q and 4Q. Would that be split kind of evenly between the 2 -- I mean, the $2 be split evenly, so you're looking at 3Q, 4Q about equivalently? Or is 3Q typically seasonally higher and then relatedly, how much of that dollar uplift, I guess, is under your control? I know you feel very comfortable with the $11 level for the full year. But maybe if you could just walk through maybe the walk from 250 to 350, say how much would be coming from M&M synergies and how much will be coming from volume and how much would be coming from internal cost reductions or something like that, that would be helpful.

Sure. So I would say -- let me again start with the end probably of that dollar uplift, the $0.75 is the bottom end of the range, which would get us kind of to the $11. We feel very much that's in our control. That's within our ability to see. I mean, again, assuming markets develop moderately in the way that we're calling out now. Combined with the controllable actions, combined with what we've seen with raw materials and energy, those things all continue as we've called out, then we clearly have a line of sight to that $11. To get to the upper end of the range, which would be more like 375 a quarter would require some further demand improvement across the end markets. And so you're right. Usually, in terms of timing, usually Q3 is a bit higher than Q4. I think we don't really have a lot of visibility on that yet. But I would say, I actually wouldn't expect them to be that much different this year. Although we typically get seasonality in Q4. That seasonality is in the Western Hemisphere. Now with the acquisition, we have much more exposure in Asia, which tends to be very strong in Q4. So I would expect for Engineered Materials, for example, that those would be similar levels in Q3 and Q4. And in fact, if we're in recovery, we've had some very healthy Q4 before when we've been in recovery as well as we have synergies building throughout the years so that our highest number for synergy will be in Q4. So I -- right now, I would say I would expect Q3 and Q4 to be similar, although typically, Q3 has been a higher quarter than Q4.

Great. And then just as a follow-up, you're going to be exiting the year theoretically at around $7 a second half level of earnings. So next year, and still, that would be maybe reflective of just a modest demand environment. So would you expect kind of continued growth as you look into '24 and similar to that second half and growing from there, is that a fair starting point?

Yes. Look, I think that's a fair starting point. I mean, obviously, we'll have some quarter-to-quarter variation because of seasonality and other things. But assuming a steady demand environment, will continue to get additional benefits from M&M. We've historically grown our own Engineered Materials business in kind of a double-digit range year-on-year. And we will get the further benefits from having Clear Lake online as well as some of the other expansions, including the integration of tow into acetyls which will continue to grow on a year-on-year basis as we move forward. So I think that's not an unreasonable place to start when you're thinking about 2024.

Come from the line of Hassan Ahmed with Alembic Global.

A question around some of the guided to sort of self-help sort of measures to boost EBITDA. I mean earlier, you were talking about being able to attain around $130 million in 2023 worth of M&M synergies as well as slightly north of $140 million from the business overall. So how is that tracking? Are those numbers still sort of attainable, beatable? Where do we stand with that?

Yes. So we had called out before 100 to 135 of M&M synergies. We fully expect to be at the top end of that range. So we are on track for that. In the second quarter, we had about $10 million of synergies from M&M. There's another $10 million or $20 million that will be added to that in the second quarter and continue to build through the year. So we feel very comfortable in achieving that $135 million of M&M synergies this year. We feel very comfortable that we have achieved the uplift from to was very obvious in the first quarter, and we also got an additional 10 million to 20 million of uplift in the first quarter from to spot sales, which was part of our model going forward that we wanted to be able. Those will be there every quarter, but I think it shows the value of having integrated it into acetyls and running it in a different way. It gives us more options to capture upside than we've had in the past. So I feel very comfortable with that number on to. I think the other thing is productivity. So we've historically achieved $100 million to $150 million a year of gross productivity. Through the first quarter, we are on track to achieve at or above that top end of that range on productivity. And these are business productivity separate from M&M synergies. So I think when we talk about self-help, we feel like we're really delivering on all of these areas as well as delivering on the volume recovery in M&M, the pricing recovery and all those things that we've laid out relative to the deal.

Fair enough. Very helpful. And as a follow-up, you had a nice sort of bump up in EM businesses EBITDA margins Q4 to Q1, around 20% EBITDA margins you guys reported for Q1. And obviously, you gave some near-term sort of guidance showing the uplift in EBITDA in that business. But from a margin perspective, longer term, as we look at sort of 2024 and beyond, where do you see EM business sort of EBITDA margins going? Because historically, pre-M&M you guys were sort of reporting sort of EBITDA margins well into the sort of low to mid-30% range. I mean, should we eventually expect sort of move towards those sort of levels of margins?

Yes. Look, in Q1, the combined Engineered Materials was about 20%. We expect that to move up across the year really as we lift the EBITDA margins on the M&M business. So by the end of the year, I think we should be more around that 23% range for the year. And I fully expect as we continue to grow M&M as we continue to grow our base business as we continue to high grade the portfolio and realize the value of the synergies that we will move into that more historical level of 25% to 30% EBITDA margins, which is actually about where we've been in the last few years.

Our next questions come from the line of Jaideep Pandya with On Field Research.

Thanks. Just want to say, it's very commendable that you guys have loaded the balance sheet with debt and not gone for the rights issue. But since the deal, the world has changed quite significantly and you're doing everything you can to sort of rightsize the business. But I just want to understand the legacy EM business, how are you making sure you're not starving this of capital because there's a lot of focus on M&M. That's my first question. The second question is on the competitive landscape in China. As a lot of Nylon 6 and 6 foliation capacity coming in China. So just putting in context of the value chain, do you actually benefit because the chain is going long in polymerization in China? Or is this going to create headaches on the pricing for you

Look, on the question around legacy EM, I think the thing to realize is we've really focused in the last 6 months in forming 1 Celanese team. So we have put an organization in place that brings all of our businesses, including Santoprene together, under new business line groups under the best set of leaders that we could pick out of the combined organization. And we've really focused on developing a culture of 1 Celanese. So we're not looking -- although for the benefits of this call, we do talk about how we're doing in each part of the business, we're not running it as 2 separate businesses. We're running it as 1 business. We have everybody on the same sales platform. We have everybody in the project model. We look at our capital processes have been combined. So we look at it in the same way. So I don't think we're at any risk of ignoring one part of the business to benefit if the other because we really are running it as one business now, even though -- because we currently still have 2 financial systems until we can integrate the IT systems, we are able to track it separately. But in terms of how we're running it, their combined sales team, we're approaching customers as 1 Celanese with a full slate of products. And if you look at -- you may be concerned because of some of the callouts we've done in the reduction of CapEx. But really, if you look at that reduction in CapEx, it's really just about reassessing the timing of our projects to really align with the revised demand outlook we have now and also integrating the M&M capacity we have into the project views to say, we may now have capacity on…

Darryl, we'll take 1 more question, please.

Our next question comes from the line of John Roberts with Credit Suisse.

You Converted M&M over to the Celanese project pipeline and backlog model. How would you characterize their number of new projects versus the legacy Celanese and backlog?

That's a good question. I'm not sure I have a number in front of me. What I'd say is we've been pleased with their willingness to use the model, if you will, and their understanding of how this adds value to the new Celanese. And I'd say the projects that are being tendered are growing as we move through this transition and people really understand what we're looking for. Again, it helps that we have combined everybody into one organization. We have one sales team. And so our growth in the project pipeline is good. We are a little bit separate from that, but we also are finding a lot of interesting things in the M&M T&I portfolio we hope to be able to bring to market. And so I think I would just expect to see it accelerate over time as we get everybody fully on board and adjusted to the Celanese way of working.

And then you've restarted the VAM unit in Germany. If there's a cold winter or some sort of energy supply disruption. Have you made enough changes to keep that plant up in that scenario? Or will you just shut it down again if we get an end new spike?

So John, I would say it was still economically attractive to run it last year when we shut it down on its own, it would have been economically attractive, but the situation there was the global demand was so low, it was more economically a taste down and supply material out of the U.S. So it really is a question of total demand profile across the globe. It is an attractive unit. It is it is cost efficient. It really was related to the high energy prices we saw there. So our intent would be to run it. We hope demand would keep up with that, but we will always look at our entirety of our portfolio and make decisions about what to run and what not to run based on what's most economically attractive.

Thank you. There are no further questions at this time. I'd like to hand the call back over to Brandon Ayache for any closing remarks.

Thank you. We'd like to thank everyone for listening in today. As always, we're available after the call for any follow-up questions you may have. Darryl, please go ahead and close up the call.

Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.